Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries

Clinical Infectious Diseases

Volumn 41, Issue 12, 2005, Pages 1783-1786

  Lawn, Stephen D ^a,b   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING COUNTRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LOWEST INCOME GROUP; LYMPHOCYTE COUNT; NOTE; OPPORTUNISTIC INFECTION; PATIENT CARE; PRIORITY JOURNAL; TUBERCULOSIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; INCIDENCE; INCOME; TUBERCULOSIS;

EID: 28744444770     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498308     Document Type: Note

References (25)

1. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137:239-50.
2. Girardi E, Antonucci G, Vanacore P, et al. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J 2004; 24:11-7.
3. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-64.
4. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038-45.
5. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19:1113-24.
6. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003; 17:2015-23.
7. Lange CG, Valdez H, Medvik K, et al. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102:154-61.
8. Hsieh SM, Hung CC, Pan SC, et al. Restoration of cellular immunity against tuberculosis in patients coinfected with HIV-1 and tuberculosis with effective antiretroviral therapy: assessment by determination of CD69 expression on T cells after tuberculin stimulation. J Acquir Immune Defic Syndr 2000; 25: 212-20.
9. Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. Chest 2002; 122:597-602.
10. Kirk O, Gatell JM, Mocroft A, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162:865-72.
11. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-6.
12. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14:1985-91.
13. Jones JL, Hanson DL, Dworkin MS, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 4:1026-31.
14. Santoro-Lopes G, de Pinho AM, Harrison LH, et al. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-6.
15. Girardi E. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. The Antiretroviral Therapy Cohort Collaboration. Clin Infect Dis 2005; 41:1772-82 (in this issue).
16. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003; 17:963-9.
17. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-73.
18. Breen RA, Smith CJ, Cropley I, et al. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS 2005; 19:1201-6.
19. Del Amo J, Petruckevitch A, Phillips AN, et al. Risk factors for tuberculosis in patients with AIDS in London: a case-control study. Int J Tuberc Lung Dis 1999; 3:12-7.
20. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
21. Cape Town TB control progress report 1997-2003. Health Systems Trust. Available at: http://www.hst.org.za. Accessed 22 August 2005.
22. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301:1535-7.
23. Seyler C, Toure S, Messou E, et al. Risk factors for active tuberculosis after antiretroviral treatment initiation in abidjan. Am J Respir Crit Care Med 2005; 172:123-7.
24. Lawn SD, Badri M, Wood R. Risk factors for tuberculosis among HIV-infected patients receiving antiretroviral treatment. Am J Respir Crit Care Med (in press).
25. Colebunders R, Ronald A, Katabira E, Sande M. Rolling out antiretrovirals in Africa: there are still challenges ahead. Clin Infect Dis 2005; 41:386-9.